enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Liczba giełd, na których notowane są akcje spółki: 1. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.
O Firmie
- Strona
- engene.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siedziba
- SAINT-LAURENT, Canada
- Prezes
- Ronald H. W. Cooper
- Pracownicy
- 81
- Akcje w Obrocie
- 67.02 mln na 2026-09-02
- Free Float
- 32.75 mln
- Kapitalizacja Rynkowa
- 132.02 mln USD
- Insiderzy
- 0.11%
- Inwestorzy Instytucjonalni
- 84.11%
- Branża (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- strata
- FCF
- −104 mln USD
- Dług
- 25.2 mln USDgotówka netto
- Zyski i FCF — za 12 miesięcy do 31.07.2026 roku (najnowszy raport firmy).
Opis
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Giełdy i Tickery
| Giełda | Ticker | Waluta | Cena | Typ |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.7 -1.73% | akcje zwykłe |
Najwięksi Akcjonariusze
| Posiadacz | Udział | Akcje | Data Raportu |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 mln | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 mln | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 mln | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 mln | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 mln | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 mln | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 mln | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 mln | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 mln | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 mln | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
